InterPAD - DETAILS

nateglinide, 105816-04-4, Starlix, Starsis, senaglinide, Fastic, AY-4166, 105816-06-6, Nateglinide [INN], Trazec, A-4166, SDZ-DJN-608, D-Nateglinide, DJN 608, DJN-608, AY4166, MFCD00875706, SDZ DJN 608, SDZ-DJN 608, AY 4166, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, A 4166, XTM4DQP5S5, CHEMBL783, (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, 41X3PWK4O2, 105746-37-0, DTXSID9040687, CHEBI:31897, n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine, N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine(Nateglinide Impurity), NSC-758695, (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine, N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-, D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-, (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, (r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, DTXCID7020687, N-((cis-4-Isopropylcyclohexyl)carbonyl)-D-phenylalanine, D-Phenylalanine, N-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-, N-((cis-4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, trans-N-((4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-, (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, SMR000466372, CAS-105816-04-4, nateglinida, nateglinidum, UNII-41X3PWK4O2, trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine, NCGC00095121-01, Nateglinide [USAN:USP:INN:BAN], Starsis (TN), Nateglinide, Starlix, YM-026, Nateglinide (Starlix), Nateglinide impurity C, Nateglinide cis Impurity, NATEGLINIDE [MI], UNII-XTM4DQP5S5, NATEGLINIDE [JAN], Nateglinide EP impurity C, NATEGLINIDE [USAN], NATEGLINIDE [VANDF], NATEGLINIDE [MART.], SCHEMBL22088, NATEGLINIDE [USP-RS], NATEGLINIDE [WHO-DD], Nateglinide impurity C [EP], MLS000759500, MLS001424043, MLS003915639, MLS006011429, BIDD:GT0257, Nateglinide cis-isomer [USP], SCHEMBL303827, NATEGLINIDE [EMA EPAR], GTPL6833, SCHEMBL7880361, SCHEMBL9232138, Nateglinide (JP17/USP/INN), CHEMBL2114389, N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine, SCHEMBL13753829, CHEBI:94617, NATEGLINIDE [ORANGE BOOK], OELFLUMRDSZNSF-BRWVUGGUSA-N, HMS2051G20, HMS2089A10, HMS2235O08, HMS3675G17, HMS3715F12, NATEGLINIDE [EP MONOGRAPH], NATEGLINIDE [USP MONOGRAPH], BCP28400, carboxamido)-3-phenylpropanoic acid, HY-B0422, Tox21_111432, BBL033469, BDBM50344967, s2489, STK647123, AKOS005577723, AKOS015841612, AKOS015960899, Nateglinide, >=98% (HPLC), solid, Tox21_111432_1, AC-1690, CCG-100898, DB00731, KS-5143, NC00148, NSC 758695, NCGC00095121-12, NCGC00095121-16, NCGC00178741-03, NCGC00271534-02, NCGC00271534-03, (R)-2-((1r,4R)-4-isopropylcyclohexane, N0912, NATEGLINIDE CIS-ISOMER [USP IMPURITY], NATEGLINIDE IMPURITY C [EP IMPURITY], NS00000602, NS00073312, SW197528-2, D01111, EN300-303645, AB00639979-06, AB00639979-08, AB00639979-09, AB00639979-11, AB00639979_12, A801324, EN300-27126236, A1-02996, Q-201449, Q2254797, Q27166439, n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine, Z1514053266, (trans-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine, Nateglinide, European Pharmacopoeia (EP) Reference Standard, ((1r,4R)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine, 2-[(4-Isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid, Nateglinide, United States Pharmacopeia (USP) Reference Standard, (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid, (2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, (R)-2-(cis-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, {N}-[({TRANS}-4-ISOPROPYLCYCLOHEXYL)CARBONYL]-D-PHENYLALANINE, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-, (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid;Nateglinide, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid

Name	Nateglinide
PubChem CID	5311309
Molecular Weight	317.4g/mol
Synonyms	nateglinide, 105816-04-4, Starlix, Starsis, senaglinide, Fastic, AY-4166, 105816-06-6, Nateglinide [INN], Trazec, A-4166, SDZ-DJN-608, D-Nateglinide, DJN 608, DJN-608, AY4166, MFCD00875706, SDZ DJN 608, SDZ-DJN 608, AY 4166, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, A 4166, XTM4DQP5S5, CHEMBL783, (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, 41X3PWK4O2, 105746-37-0, DTXSID9040687, CHEBI:31897, n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine, N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine(Nateglinide Impurity), NSC-758695, (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine, N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-, D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-, (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, (r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, DTXCID7020687, N-((cis-4-Isopropylcyclohexyl)carbonyl)-D-phenylalanine, D-Phenylalanine, N-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-, N-((cis-4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, trans-N-((4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-, (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, SMR000466372, CAS-105816-04-4, nateglinida, nateglinidum, UNII-41X3PWK4O2, trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine, NCGC00095121-01, Nateglinide [USAN:USP:INN:BAN], Starsis (TN), Nateglinide, Starlix, YM-026, Nateglinide (Starlix), Nateglinide impurity C, Nateglinide cis Impurity, NATEGLINIDE [MI], UNII-XTM4DQP5S5, NATEGLINIDE [JAN], Nateglinide EP impurity C, NATEGLINIDE [USAN], NATEGLINIDE [VANDF], NATEGLINIDE [MART.], SCHEMBL22088, NATEGLINIDE [USP-RS], NATEGLINIDE [WHO-DD], Nateglinide impurity C [EP], MLS000759500, MLS001424043, MLS003915639, MLS006011429, BIDD:GT0257, Nateglinide cis-isomer [USP], SCHEMBL303827, NATEGLINIDE [EMA EPAR], GTPL6833, SCHEMBL7880361, SCHEMBL9232138, Nateglinide (JP17/USP/INN), CHEMBL2114389, N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine, SCHEMBL13753829, CHEBI:94617, NATEGLINIDE [ORANGE BOOK], OELFLUMRDSZNSF-BRWVUGGUSA-N, HMS2051G20, HMS2089A10, HMS2235O08, HMS3675G17, HMS3715F12, NATEGLINIDE [EP MONOGRAPH], NATEGLINIDE [USP MONOGRAPH], BCP28400, carboxamido)-3-phenylpropanoic acid, HY-B0422, Tox21_111432, BBL033469, BDBM50344967, s2489, STK647123, AKOS005577723, AKOS015841612, AKOS015960899, Nateglinide, >=98% (HPLC), solid, Tox21_111432_1, AC-1690, CCG-100898, DB00731, KS-5143, NC00148, NSC 758695, NCGC00095121-12, NCGC00095121-16, NCGC00178741-03, NCGC00271534-02, NCGC00271534-03, (R)-2-((1r,4R)-4-isopropylcyclohexane, N0912, NATEGLINIDE CIS-ISOMER [USP IMPURITY], NATEGLINIDE IMPURITY C [EP IMPURITY], NS00000602, NS00073312, SW197528-2, D01111, EN300-303645, AB00639979-06, AB00639979-08, AB00639979-09, AB00639979-11, AB00639979_12, A801324, EN300-27126236, A1-02996, Q-201449, Q2254797, Q27166439, n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine, Z1514053266, (trans-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine, Nateglinide, European Pharmacopoeia (EP) Reference Standard, ((1r,4R)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine, 2-[(4-Isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid, Nateglinide, United States Pharmacopeia (USP) Reference Standard, (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid, (2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, (R)-2-(cis-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, {N}-[({TRANS}-4-ISOPROPYLCYCLOHEXYL)CARBONYL]-D-PHENYLALANINE, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-, (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid;Nateglinide, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid
Drug Type	Small molecule
Formula	C₁₉H₂₇NO₃
SMILES	CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O
InChI	1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
InChIKey	OELFLUMRDSZNSF-OFLPRAFFSA-N
CAS Number	105816-06-6
ChEMBL ID	CHEMBL783
ChEBI ID	CHEBI:31897
TTD ID	D06PSS
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Nateglinide
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.